The CEO's substantial personal investment suggests strong conviction ahead of potential catalysts; traders should monitor for upcoming clinical updates or partnerships.
GENB drugs
GENB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $11.93entry
- T+1 · 9mo ago −2.93%α −3.64% · $11.58
- T+5 · 8mo ago +2.35%α +2.81% · $12.21
- T+20 · 8mo ago +4.78%α +9.19% · $12.50
- T+60 · 6mo ago +9.72%α −1.19% · $13.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Generate Biomedicines CEO Michael Nally led a $240,000 open-market share purchase, joined by three other executives in smaller buys, signaling strong insider confidence. The cluster includes several non-cash derivative conversions with no economic impact.
Key Financial Metrics
Key Facts
- CEO Michael Nally purchased 20,000 shares for $240,000 in open-market transactions on March 4, 2026.
- President & CFO Jason Silvers, Chief People Officer Beth Grous, and Jane Mendillo each made open-market purchases totaling $36,800 combined.
- Four derivative conversions (totaling over 26 million shares) were non-cash events with $0 transaction value and no economic significance.
- Total open-market buying in the cluster: $277K across 4 insiders, matching recent 30-day insider activity.
- Insider purchases represent approximately 0.017% of the company's $1.6B market cap, modest in size but highly concentrated among C-suite executives.
Financial Impact
$277,000 in net insider buying over 7 days, all by corporate insiders at C-suite level
Risk Factors
- The dollar amount, while meaningful for insider activity, is small relative to market cap and unlikely to move the stock directly.
- No accompanying fundamental news or guidance update in this filing window.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-GENB-1772834153988 |
Track record
11 reports on GENB
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +14.28% at T+20 after the Oct 1, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 5/10 Entry $12.57 Now $10.49 +16.55% settles Dec 11
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $12.57 Now $10.49 −16.55% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $13.85 Now $10.49 −24.26% settles Dec 2
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $14.46 Now $10.49 −27.46% settles Nov 30
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $12.52 to $13.49 Now $10.49 −16.21% ▲ +7.75% +9.02% vs SPY
- Oct 1, 20266w ago Press Release Bullish 5/10 Entry $13.80 to $15.77 Now $10.49 −23.99% ▲ +14.28% +13.57% vs SPY
- May 7, 202627w ago 8-K Bearish 6/10 Entry $13.59 to $12.91 Now $10.49 +22.81% ▲ +5.00% +8.14% vs SPY
- Mar 2, 202637w ago Insider Cluster Bullish 7/10 Viewing Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
- Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
- Feb 27, 202637w ago 424B4 Bearish 7/10 Entry $12.17 to $11.51 Now $10.49 +13.80% ▲ +5.42% −2.52% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers